Ozempic and NAION: Serious Vision Changes and Possible Permanent Loss
Recent studies have raised concerns about a potential link between Ozempic (semaglutide) and serious vision problems, particularly the rare condition known as non-arteritic anterior ischemic optic neuropathy (NAION).
This eye disorder occurs when blood flow to the optic nerve is interrupted, leading to sudden vision loss in one eye, and is often referred to as a “stroke of the optic nerve.”
According to research published by a team from Massachusetts Eye and Ear, a Harvard-affiliated hospital, patients who took Ozempic or Wegovy were found to be at a heightened risk for developing NAION.
The study revealed that those taking these semaglutide-based drugs for weight loss were seven times more likely to experience the condition than those on other obesity treatments .
While these findings are significant, the researchers emphasized that the study does not yet prove a causal link between Ozempic and NAION.
However, the association is strong enough to warrant further investigation.
The study, which analyzed six years of medical data, focused on more than 16,000 patients in the Boston area, revealing that 37 individuals across both diabetes and weight loss groups developed NAION after starting semaglutide.
In the diabetes group, patients on semaglutide had a fourfold increased risk of NAION compared to those on other treatments.
What is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)?
Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare eye condition that occurs when blood flow to the optic nerve becomes restricted, causing damage to the nerve fibers that transmit visual information from the retina to the brain.
The condition is often referred to as an “eye stroke” because it results from impaired circulation within the small blood vessels that supply the optic nerve.
NAION typically causes sudden, painless vision loss in one eye and may also produce blind spots, reduced peripheral vision, diminished color perception, or permanent visual impairment.
Unlike blurry vision caused by temporary changes in blood sugar levels or shifts in the shape of the eye’s lens, NAION involves structural injury to the optic nerve itself and can result in irreversible damage.
NAION is considered the most common acute optic nerve disorder in older adults and is frequently associated with underlying vascular risk factors such as diabetes, high blood pressure, sleep apnea, cardiovascular disease, and other conditions affecting circulation.
Because optic nerve tissue has limited ability to regenerate after ischemic injury, NAION is widely recognized as a potentially blinding eye disease that can have lifelong consequences for affected patients.
Semaglutide and NAION: What Current Research Shows
The July 2024 Harvard study from Massachusetts Eye and Ear found that individuals prescribed Ozempic and other GLP-1 drugs were at a heightened risk for developing NAION.
Recent research suggests semaglutide drugs may be linked to serious eye conditions, including non-arteritic anterior ischemic optic neuropathy (NAION).
Research into semaglutide and vision loss has expanded rapidly as physicians investigate reports of non-arteritic anterior ischemic optic neuropathy (NAION), a condition involving reduced blood flow to the optic nerve that can cause sudden, painless vision loss.
Several studies have identified an association between semaglutide use and a higher incidence of NAION, although researchers continue to examine the biological mechanisms involved and whether other patient-specific risk factors contribute to the condition.
A study published in August 2024 found a higher risk of NAION among patients prescribed semaglutide compared to individuals using non-GLP-1 receptor agonist medications, with 17 cases occurring in the semaglutide group versus six in the comparison group.
Additional research has also explored other retinal and optic nerve findings, including diabetic retinopathy progression and paracentral acute middle maculopathy, as investigators work to better understand the potential long-term effects of GLP-1 medications on ocular health.
Studies and regulatory findings include:
WHO and EMA Warnings About Semaglutide and NAION
In June 2025, the World Health Organization alerted healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide medications, including Ozempic, Rybelsus, and Wegovy.
The WHO advised patients using semaglutide to seek medical care immediately if they experience sudden vision loss or rapidly worsening eyesight.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee also concluded that NAION should be listed as a very rare side effect of semaglutide medications after reviewing clinical trials, post-marketing surveillance, non-clinical data, and published medical literature.
The EMA stated that NAION may affect up to 1 in 10,000 people taking semaglutide and recommended that semaglutide treatment be stopped if NAION is confirmed.
These regulatory actions marked a major development in the medical and legal scrutiny surrounding semaglutide-related optic nerve injuries and permanent vision loss.
Symptoms of NAION and Sudden Vision Loss
NAION often develops without warning and typically causes sudden, painless vision loss in one eye due to reduced blood flow to the optic nerve.
Unlike age-related macular degeneration, which generally progresses gradually over time, NAION can occur abruptly and may result in permanent visual impairment within hours or days.
Although diabetic patients and individuals with vascular disease face a higher baseline risk, anyone experiencing sudden changes in vision should seek immediate medical attention to protect their eye health and identify potential underlying conditions affecting the body.
Common symptoms of NAION may include:
- Sudden vision loss in one eye
- Blurred or dimmed vision
- Loss of peripheral vision
- Blind spots in the visual field
- Reduced color perception
- Dark or gray areas in vision
- Decreased contrast sensitivity
- Visual field defects affecting upper or lower vision
- Optic nerve swelling detected during an eye examination
GLP-1 Vision Loss MDL 3163
Federal lawsuits involving GLP-1 gastrointestinal injuries have already been consolidated in MDL No. 3094 in the Eastern District of Pennsylvania.
A separate multidistrict litigation, MDL No. 3163, was created for claims alleging that GLP-1 receptor agonist drugs caused non-arteritic anterior ischemic optic neuropathy (NAION) and related vision loss injuries.
MDL No. 3163 is also centralized in the Eastern District of Pennsylvania and is being handled before Judge Karen S. Marston, the same judge overseeing the gastrointestinal injury litigation.
The separate MDL structure reflects the different medical evidence, expert testimony, causation issues, and injury mechanisms involved in NAION claims compared to gastroparesis, bowel obstruction, and other gastrointestinal injury cases.
The vision loss MDL involves allegations concerning GLP-1 medications used for type 2 diabetes and chronic weight management, including Ozempic, Wegovy, Saxenda, and Trulicity.
These cases remain in active pretrial proceedings, where the parties are expected to address discovery, scientific evidence, expert testimony, case-specific injury proof, and the adequacy of manufacturer warnings.
No global settlement has resolved GLP-1 NAION claims at this stage.
Allegations in GLP-1 vision loss lawsuits include:
- GLP-1 receptor agonist medications caused or contributed to NAION
- Patients developed sudden, painless vision loss after using semaglutide or other GLP-1 medications
- Manufacturers failed to adequately warn patients and prescribing physicians about the reported risk of NAION
- Drug labels did not sufficiently address the potential for optic nerve ischemia or permanent vision loss
- Patients and physicians may have made different treatment decisions if stronger warnings had been provided
- Plaintiffs suffered permanent visual impairment, loss of peripheral vision, blind spots, or blindness
- Manufacturers continued marketing GLP-1 medications despite emerging clinical studies, adverse event reports, and regulatory safety concerns
The Rise of Lawsuits Against Ozempic, Wegovy, and Other GLP1 Drug Manufacturers
The majority of the Ozempic Lawsuits center around gastrointestinal issues that patients have suffered after taking Ozempic and similar drugs like Wegovy, Mounjaro, Trulicity, and potentially more.
These problems range from severe nausea and vomiting to more serious conditions like gastroparesis.
Gastroparesis is a disorder where the stomach’s ability to move food is slowed down or completely stopped, leading to stomach paralysis.
Patients dealing with these complications argue that they weren’t adequately warned about the risks.
Plaintiffs claim that Novo Nordisk and Eli Lilly, the makers of these drugs, failed to provide proper warnings about these potential side effects.
According to the lawsuits, the companies knew, or should have known, about these risks but did not alert the medical community or the public in time.
The FDA has acknowledged the reports but has not issued an official warning about Ozempic despite the growing number of patients complaining of gastroparesis and eye conditions.
In 2023, the FDA required the manufacturers of Ozempic and Wegovy to update the drug’s warning label to include the risk of bowel obstruction, a severe gastrointestinal side effect.
Who May Qualify for an Ozempic Vision Loss Lawsuit?
Individuals who developed non-arteritic anterior ischemic optic neuropathy (NAION), sudden vision loss, or other documented optic nerve injuries after taking Ozempic may qualify to pursue legal action.
Most cases under investigation involve patients who used semaglutide-based medications and later experienced sudden, painless vision loss that was diagnosed by an ophthalmologist, neuro-ophthalmologist, or other eye specialist.
Medical records documenting NAION, optic nerve swelling, visual field defects, or permanent visual impairment may play an important role in evaluating a potential claim.
Plaintiffs generally must demonstrate a timeline showing that vision symptoms developed after beginning treatment with Ozempic, Wegovy, Rybelsus, or another semaglutide medication.
Diagnostic testing such as visual field examinations, retinal imaging, optic nerve evaluations, and ophthalmology records may also help support a claim.
Because NAION can occur in people with diabetes, hypertension, sleep apnea, and other vascular conditions, each case typically requires an individualized review of the patient’s medical history and risk factors.
Attorneys reviewing these claims often examine prescription records, treatment history, symptom onset, diagnostic findings, and the extent of any permanent vision impairment.
Individuals who experienced sudden vision loss after taking semaglutide medications may benefit from having their case reviewed to determine whether they may qualify for the ongoing GLP-1 vision loss litigation.
Evidence Used in Ozempic Vision Loss Claims
Evidence plays a critical role in establishing when vision symptoms began, confirming the diagnosis, and evaluating whether there may be a connection between the injury and medication use.
Because NAION and other optic nerve disorders can occur in patients with preexisting vascular risk factors, medical documentation is often necessary to assess causation and rule out alternative explanations.
Attorneys reviewing claims involving once-weekly semaglutide medications typically analyze prescription history, ophthalmology records, diagnostic testing, and treatment timelines when evaluating potential cases.
Evidence commonly used in Ozempic vision loss claims may include:
- Prescription records showing Ozempic, Wegovy, Rybelsus, or other semaglutide use
- Pharmacy records documenting dosage history and duration of treatment
- Ophthalmology and neuro-ophthalmology records
- NAION diagnosis records
- Visual field testing results
- Optical coherence tomography (OCT) imaging
- Fundus photography and retinal imaging
- Optic nerve examination findings
- Emergency room and hospital records related to vision loss
- Physician notes documenting symptom onset and progression
- Medical records addressing preexisting eye or vascular conditions
- Records of follow-up treatment, rehabilitation, or permanent visual impairment
- Employment records demonstrating lost income or occupational limitations caused by vision loss
What To Do If You Suspect Vision Loss Due to Ozempic and Other Semaglutide Drugs
If you suspect that Ozempic or another semaglutide drug has affected your vision, act quickly.
Early intervention may help prevent further damage and protect your legal rights. Here are the steps you should take.
Seek Medical Attention Immediately
If you notice any changes in your vision, such as blurred vision, difficulty focusing, or sudden loss of sight, schedule an appointment with your healthcare provider right away.
Doctors can evaluate your symptoms, check for conditions like diabetic retinopathy or optic nerve damage, and help you determine whether Ozempic could be a contributing factor.
Schedule an Eye Exam
Your healthcare provider will likely recommend seeing an eye doctor or specialist for a thorough examination.
Regular eye exams are important if you’re taking medications that can potentially affect your vision or if you’re experiencing worsening symptoms.
An eye specialist can help track any changes and suggest treatment options if necessary.
Document Your Symptoms
Keep a detailed record of your vision changes, including the dates and severity of symptoms.
This documentation will be helpful for your healthcare provider and may serve as evidence in any legal action you may pursue.
Make sure to note any conversations with your doctors and test results as well.
Contact the Ozempic Lawyers at TorHoerman Law
If you suspect that Ozempic is responsible for your vision loss, it’s a good idea to consult with a lawyer experienced in pharmaceutical lawsuits.
The Ozempic lawyers at TorHoerman Law can help you understand your rights and determine whether you may be eligible to join the ongoing Ozempic Lawsuit.
TorHoerman Law: Ozempic Attorneys
Vision loss and other eye-related side effects from Ozempic are serious concerns that require immediate attention.
If you’re experiencing symptoms like blurred vision or more severe eye problems, take action quickly by consulting with your healthcare provider and scheduling an eye exam.
Protecting your health is the first priority.
Our Ozempic Lawyers are keeping tabs on the possible risk of serious eye injuries and vision loss in relation to Ozempic use.
Contact us for a free consultation.
You can also use the chatbot on this page to find out if you’re eligible for an Ozempic Lawsuit.
